




# RÉSEAU SATT



## 13 SATT

Elles sont connectées au quotidien à plus de **150 000 chercheurs** et offrent un accès privilégié aux innovations des laboratoires publics.

## 1 RÉSEAU NATIONAL

Permettant de **simplifier et d'accélérer** le rapprochement des entreprises avec les innovations disponibles.



RÉSEAU SATT

80%

De la recherche  
publique française



Santé &  
Biotech



Agronomie  
Ecologie &  
Environnement



Sciences de  
l'ingénieur  
& STIC



Chimie &  
Matériaux



Sciences  
humaines  
& sociales



## Deux modes d'action

### ➔ PUSH

- **Détecter** les résultats de recherche dans les laboratoires
- **Investir** pour développer les innovations à fort potentiel
- **Licensing** à des partenaires industriels ou des futures startups

### ← PULL


- **Analyse** des besoins spécifiques des industriels
- **Repérage** technologique
- **Construction** de partenariats industriels

## NOTRE QUOTIDIEN

- **Dérisquer** les technologies
- **Créer** de la valeur économique
- **Combl**er le gap de la chaîne d'innovation



# Pourquoi innover avec les SATT ?



# Les SATT en Chiffres



**17 674**

Projets innovants  
détectés



**3 815**

Brevets  
déposés



**1 683**

Transferts  
de technologies



**755**

Startups  
DeepTech créées



**1,5**

Md€ levés  
par ces startups

# Direction des Partenariats Industriels



Mise en place en juillet 2022, la **Direction des Partenariats Industriels** est une équipe nationale dédiée au **transfert de technologies** et au  **rapprochement auprès des entreprises**



## ACCÉLÉRER

La mise en relation et la discussion sur une technologie identifiée

**PUSH**



## FACILITER

L'identification de solutions en réponse aux besoins industriels

**PULL**

# Direction des Partenariats Industriels



**Laurent  
AURET**

*Directeur des  
Partenariats Industriels*  
laurent.auret@satt.fr  
+33 642 621 355



**Sandrine  
GARY-TREHIN**

*Responsable filière  
GREENTECH*  
sandrine.gary-trehin@satt.fr  
+33 761 052 223



**Hervé  
ANSANAY**

*Responsable filière  
BIOTECH*  
herve.ansanay@satt.fr  
+33 634 104 219



**Aurélie  
LEMONDE**

*Responsable filière  
NUMTECH*  
aurelie.lemonde@satt.fr  
+33 666 561 123



**Nicolas  
LAMOUREUX**

*Responsable filière  
MEDTECH*  
nicolas.lamoureux@satt.fr  
+33 764 183 636

## **1** INTERLOCUTEUR UNIQUE

**Une porte d'entrée unique par filière :** Un gain de temps pour les entreprises qui souhaitent avoir une réponse nationale en termes d'offres et de services.

## **4** EXPERTS SECTORIELS


**Une vision sectorielle nationale :** Un service d'accompagnement à travers l'offre et le catalogue mutualisé de technologies des SATT.




# « LES x Hervé Ansanay »




# Les procédures possibles avant le programme de maturation



# Rôles & missions en « Techno Push »



# Rôles & missions en « Market Pull »



# Des exemples de projets en recherche de partenaires



## TATLAT

Technology matured by 


Development of small molecules acting as latency reversing agents that can be used in combination with antiretroviral therapies in a shock&kill strategy against HIV-1

#HIV-1

#Latency Reversing Agents

#Shock&Kill Strategy


Although combined antiretroviral therapy (cART) successfully decreases plasma viremia to undetectable levels, the complete eradication of HIV-1 remains impractical because of the existence of a viral reservoir. The Shock & Kill strategy is based on the use of LRAs (latency reversing agents) to re-activate reservoir quiescent cells in order to kill them. Various cytokines, protein kinase C activators/agonists, and histone deacetylase inhibitors (HDACi) have been used as LRAs, but their unacceptable side effects and/or low efficiencies limit their clinical use. In this project, using molecular modeling, the team has screened and selected new chemical entities acting as LRAs that do not target a cellular protein but a viral protein.



# TECHNOLOGY BIOTECH



## DELIS-ALZ

Technology matured by  **CONNECTUS**  
OFFICIAL INNOVATION PROVIDER

**New sigma1 agonists to target cognitive & neurodegenerative diseases. Best-in-class small molecule, with higher safety and activity than competitors.**

#CNS

#Neurodegeneration

#Small Molecule

The endoplasmic reticular (ER) protein sigma-1 receptor has been implicated in many CNS disorders. The DELIS project led to the development of 2 chemical series of  $\sigma_1$  ligands receptor with proven efficacy as cognitive enhancers against cognitive deficits associated with Schizophrenia (CIAS) and Alzheimers' disease (ALZ)-type dementia.

We are looking for out-licensing our preclinical stage NCEs with...

- High affinity to  $\sigma_1$  & high selectivity  $\sigma_1$  vs  $\sigma_2$
- Good ADME-Tox profile, no off targets
- Bioavailability (cross the BBB) allowing in vivo efficacy via P.O. administration
- Good pharmacological profiles in cognitive models CIAS & ALZ
- Efficacy observed in a cognitive impairments model using chronic PCP injection (Subcontractor)
- Preliminary effect on locomotor impairments in ALS ZEBRAFISH model (Subcontractor)




# TECHNOLOGY BIOTECH



## THERACELL

Cell therapy from short-lived activated T-cell

Technology matured by   
technology transfer & startup building  
Grenoble Alpes

#CTEACD

#Reactivity in case of  
pandemic infections


#GVH

Solution for harvesting short-lived hyper-activated T cells from convalescent patients for re-injection into other primary infected patients

Proof of concept validated in two mouse models : Influenza and Covid.

Applications are multiple but particular needs have been identified for CMV and GVH.

The next step will be to study the feasibility of extracting cells from cord blood in order to guarantee supply and stock.




# TECHNOLOGY BIOTECH



## GLIOVED

First-in-class OSBP inhibitors as new chemical entities for the treatment of cancer.

Technology matured by  **SATT**  
PARIS-SACLAY

#Glioblastoma

#First-in-class

#Anticancer

Glioblastoma is the most well-known form of primary tumor of the brain. It affects adults of all ages and is resistant to current treatments, which leads to patient death within 18 months.

The GLIOVED project is based on the identification of new derivatives of natural plant products (of the *Euphorbiaceae* family) that act on a new biological target.

Results from the maturation program:

New analogs optimized and shortened synthetic process with improved yield

Confirmed MOA

Satisfactory BBB penetration

Exclusion of major safety alerts

In vitro cytotoxicity profile

First encouraging in vivo data in glioblastoma mouse model



**CONTACT BUSINESS**

Hervé ANSANAY | BIOTECH Alliance Manager | [herve.ansanay@satt.fr](mailto:herve.ansanay@satt.fr)

## X Fragile SYNDROME

Technology matured by



A new treatment for X fragile syndrome using repurposed drug

#XFragile


#Repurposing

#Small Molecules

Fragile X syndrome (FXS) is a genetic disorder characterized by mild-to-moderate intellectual disability. Furthermore, these patients have features of autism such as problems with social interactions and delayed speech.

Currently there is no treatment for X fragile syndrome available.

The research team has identified a new target to treat symptoms of this disease and characterized drugs that alleviate patients' condition especially with regards to their social interactions.



# TECHNOLOGY BIOTECH



## CAPTEUR pH

Optical sensor for calibration free pH measurement

Technology matured by



#pHmeter


#sensor

#opticalfiber

The innovation is a pH sensor without calibration which consists of an optical fiber comprising pH sensitive fluorescent molecules. The latter are excited via the optical fiber and emit a fluorescence spectrum. This spectrum is converted into a pH value via a dedicated and validated mathematical physico-chemical model (pH range from 0 to 8 validated).

This model eliminates the need for calibration which brings reliability and precision to pH measurement.

- Continuous measurement (real-time process monitoring)
- Low manufacturing cost
- Allows measurements in world record small volumes (nL)



## SONOCOCTAIL

Technology matured by



Ultrasound-sensitive perfluorocarbon nanodroplets for  
theranostic applications


#Nanodroplets

#Ultrasound

#Theranostic

*Developing an innovative therapeutic tool that will carry drugs directly into the Central Nervous System (CNS) compartment by opening first the blood-brain barrier (BBB), then the shell of the drug carrier itself, through ultrasound exposure.*

- Synthesis of perfluorocarbon droplets stabilized with biocompatible tailored-made fluorinated surfactants
- Capacity to produce dry and stable formulations with controlled polydispersity indexes (for several months)
- No sign of acute toxicity after i.v. administration of 2 g/kg into mice
- Drug loading in high concentration and ultrasound-induced drug release
- The perfluorocarbon droplets are small enough to cross the BBB after ultrasound. The fluorescence is clearly visible indicating the extravasation of fluorescent droplets





# 26 STARTUPS SOUTENUES PAR LES SATT ISSUES DE LA RECHERCHE PUBLIQUE MOBILISÉES CONTRE LE **#COVID19**

+ de **25** projets  
de maturation



**21** startups pour  
diagnostiquer et soigner



**SATT**  
Réseau  
Les Sociétés d'Accélération  
du Transfert de Technologies

**5** startups pour la vie en  
confinement et l'aide  
aux entreprises



# MERCI !

[www.satt.fr](http://www.satt.fr)

